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Background: Secondary hyperparathyroidism is a common complication of chronic kidney 
disease and is managed using vitamin D replacement therapy. Very few studies have examined 
the effectiveness of pulse alfacalcidol therapy in comparison to daily oral alfacalcidol therapy 
in suppressing serum parathyroid hormone (PTH) levels in hemodialysis patients. The aim 
of this randomized controlled trial was to replicate the findings of prior studies comparing 
effectiveness of pulse oral alfacalcidol therapy versus daily oral alfacalcidol therapy in sup-
pressing PTH after 13 weeks of therapy using a Palestinian sample of hemodialysis patients, 
and to identify demographic and biomedical characteristics of patients that are independently 
associated with PTH levels.
Methods: One hundred and sixty-seven patients completed the study, 88 in the daily group and 
79 in the pulse group. The pulse group had more clinically significant reduction in mean PTH 
level by 75 pg/dL at 13 weeks than the daily group, but this was not statistically significant.
Results: The effect of alfacalcidol therapy on metabolism of phosphate and corrected calcium 
levels was comparable in both groups, and pulse therapy was not associated with increased risk 
of hypercalcemia and hyperphosphatemia. Serum PTH levels were independently and inversely 
associated with older age and diabetes.
Conclusion: Switching daily alfacalcidol therapy to thrice-weekly alfacalcidol pulse therapy 
seems safe and convenient, especially for hemodialysis patients with poor compliance with treat-
ment. This study also highlights the importance of monitoring and preventing malnutrition in 
hemodialysis patients and maintaining optimal glycemic control in diabetic hemodialysis patients.
Keywords: end-stage kidney disease, hemodialysis, alfacalcidol, parathyroid hormone, hyper-
parathyroidism, randomized controlled trials, pulse therapy
Background
Secondary hyperparathyroidism, characterized by elevated serum parathyroid hor-
mone (PTH), autonomous secretion parathyroid hyperplasia, is a common complica-
tion of chronic kidney disease.1,2 Progression of secondary hyperparathyroidism in 
chronic kidney disease is attributed to a combination of factors, including reduction 
in  vitamin D synthesis, hyperphosphatemia, hypocalcemia, and PTH skeletal resis-
tance.3,4 This state of mineral metabolism imbalance is independently associated with 
increased risk of mortality from cardiovascular disease and morbidity, such as bone 
disease and fractures, among patients with end-stage renal disease on maintenance 
hemodialysis.5–9 Vitamin D replacement therapy with alfacalcidol (1α-hydroxyvitamin 
D3) is widely used in the treatment of secondary hyperparathyroidism in hemodialy-
sis patients. Prior studies have shown that alfacalcidol, whether administered orally 
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or intravenously, is effective in suppressing PTH secretion 
without significant increase in the risk of hypercalcemia 
and hyperphosphatemia.10,11 Additionally, prior studies have 
demonstrated that pulse alfacalcidol therapy is effective 
in suppressing PTH as daily oral alfacalcidol therapy.12,13 
However, some studies recommend the use of pulse oral 
alfacalcidol in hemodialysis patients for its ease of adminis-
tration during hemodialysis sessions, treatment compliance, 
and cost-effectiveness advantages.14,15
Until now, only very few studies have compared the 
effects of pulse oral alfacalcidol therapy versus daily oral 
alfacalcidol therapy in suppressing PTH among hemodialy-
sis patients.12,13 One study only included a relatively small 
number of hemodialysis patients (16 patients in the daily 
group and 18 patients in the pulse group). Also, the findings 
of these studies regarding the effectiveness of pulse oral 
alfacalcidol therapy versus daily oral alfacalcidol therapy 
in suppressing PTH were unadjusted and did not account 
for the independent effects of various demographic and 
biomedical characteristics of hemodialysis patients on PTH 
levels (for example, age, duration on hemodialysis, diabetic 
status), which were reported as significant predictors of PTH 
levels among hemodialysis and peritoneal dialysis patients.16 
Identifying demographic and biomedical characteristics that 
independently affect PTH levels among hemodialysis patients 
is important. Such information can be used in clinical practice 
in developing individualized treatment plans for hemodi-
alysis patients, which may help in achieving optimal target 
ranges for PTH and maintain mineral metabolism balance. 
The aim of this randomized controlled trial was to replicate 
the findings of previous studies comparing effectiveness of 
pulse oral alfacalcidol therapy versus daily oral alfacalcidol 
therapy in suppressing PTH using a Palestinian sample of 
hemodialysis patients, and to identify demographic and 
biomedical patients’ characteristics independently associated 
with PTH levels.
Methods
Study design, population, and setting
This randomized controlled study was conducted in the 
hemodialysis unit at An-Najah National University Hospital, 
Nablus, Palestine. The study lasted for 13 weeks (October 1, 
2016, to January 1, 2017). The Institutional Review Board 
of College of Medicine and Health Sciences at An-Najah 
National University granted ethical approval for this study 
under ethical approval archive number 101/OCT/2015. All 
patients signed informed consent for participation in the 
study. Subjects had to meet the following eligibility criteria 
for inclusion in the study: age ≥18 years old and with mean 
values from three consecutive readings of <10.5 mg/dL for 
serum corrected calcium, <8.5 mg/dL for serum phosphorus, 
and >180 pg/mL for PTH (more than three times the upper 
normal limit of PTH [60 pg/mL]). Subjects who did not meet 
the inclusion criteria and those with any concomitant chronic 
or malignant liver disease were excluded. All patients were 
on regular three hemodialysis sessions per week (4 hours 
per  session) using a dialysate calcium concentration of 
1.25 mmol/L.
Treatment groups
We used the random number generation function in the 
Statistical Package for Social Sciences (SPSS, version 23.0, 
IBM Corp., Armonk, NY, USA) to randomize patients to 
receive either daily oral dose of alfacalcidol (daily group) 
or thrice-weekly oral dose of alfacalcidol (pulse group). The 
alfacalcidol oral tablets preparations available in the unit were 
0.25 mcg and 1.0 mcg. The alfacalcidol dosage for every 
patient in both treatment groups was based on baseline serum 
PTH levels and was adjusted monthly based on laboratory 
findings as described by KDIGO criteria.23 The thrice-weekly 
alfacalcidol for each patient in the pulse group was calculated 
using the following formula: thrice-weekly dose = (daily 
dose ×7)/3. Then the resulting dosage of alfacalcidol was 
rounded to the multiples of 0.25 mcg. Patients in the daily 
group received their individualized dosage of alfacalcidol 
as usual (7 days per week), while patients in the pulse group 
received their individualized alfacalcidol dosage at the end 
of each hemodialysis session. Phosphate binders used in the 
study for all patients were calcium carbonate (600 mg tablet), 
calcium acetate 700 mg tablet, and Sevelamer hydrochloride 
800 mg tablet.
Measurements
Corrected serum calcium and phosphate were measured at 
baseline and were repeated on monthly basis, while serum 
PTH was measured at baseline and at the end of the study. 
However, any extremes values for corrected serum calcium 
or phosphate and for serum PTH were repeated after 2 weeks 
and 1 month, respectively. The alfacalcidol dosage was 
discontinued if the PTH reading was less than 150 pg/mL, 
and the serum PTH was repeated next month. Corrected 
serum calcium level was determined using the formula: 
albumin-adjusted serum calcium concentration (mg/dL) 
= measured serum calcium concentration (mg/dL) + 0.8 
× [4 − serum albumin concentration (g/dL)].24 All blood 
samples from patients were drawn from the dialyzer line 
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before starting hemodialysis session. Laboratory serologi-
cal tests were carried out at An-Najah National University 
Hospital laboratories.
Statistical analysis
Descriptive statistics were used to summarize demographic 
and biomedical characteristics of patients. Frequencies with 
percentages were used to summarize categorical variables 
and mean with standard deviation  was used for continuous 
variables. Independent samples t-test and χ2 test were used to 
examine for any statistically significant differences between 
treatment groups on baseline demographic and biomedical 
characteristics. Paired-samples t-test was used for comparing 
changes in serum PTH, corrected calcium, and phosphate lev-
els at baseline and at 13 weeks. Repeated measures analyses 
using a linear mixed-modeling approach were used to esti-
mate effect of independent variables (treatment group [daily, 
pulse], age, gender [female, male], diabetic status [yes, no], 
and duration of dialysis in years) on changes in serum PTH, 
corrected calcium, and phosphate levels at 13 weeks with 
their respective baseline levels. All tests were two-sided. A 
P-value less than 0.05 was considered statistically significant. 
All analyses were conducted using SPSS computer program 
(version 23.0, IBM Corp).
Results
Baseline characteristics of patients
One hundred and eighty-four patients were enrolled at the 
beginning of the study, 93 in the daily group and 91 in the 
pulse group. Only 167 patients completed the study, 88 in 
the daily group and 79 in the pulse group. In the daily group, 
4 patients died and one patient dropped out for undergoing 
renal transplantation. Reasons for death in the daily group 
were due to myocardial infarction (2 patients), colon cancer 
(1 patient), and heart failure (1 patient). In the pulse group, 
6 patients died, one patient dropped out for undergoing renal 
transplantation, one patient was not compliant with hemodi-
alysis, and four patients decided to withdraw from the study 
(two of them reported gastrointestinal disturbances). Causes 
for death in the pulse group were due to cerebrovascular 
accidents (3 patients), sepsis (2 patients), and pulmonary 
embolism (1 patient).
The baseline demographic and biomedical characteris-
tics of patients who completed the study are presented in 
Table 1. There were no statistically significant differences 
between the daily and pulse groups in age; gender; duration 
on dialysis; diabetic status; serum PTH, corrected calcium, 
phosphorus levels, and therapeutic doses for alfacalcidol, 
 calcium carbonate and calcium acetate, and Sevelamer 
hydrochloride.
Therapeutic efficacy
At the end of the study, PTH levels were lower in both treat-
ment groups as compared with baseline levels (Table 2). The 
mean reduction in PTH from baseline in the daily group was 
43 pg/mL, but this was not statistically significant (P=0.159). 
However, the mean reduction in PTH from baseline in the 
pulse group was 118 pg/mL and statistically significant 
(P<0.001); Figure 1.
After 13 weeks of therapy, there were no statistically 
significant differences between the two groups in propor-
tions of patients reaching therapeutic end point for PTH 
level (150–300 pg/mL). The therapeutic end point for PTH 
levels was roughly equal (38%) in both groups. Similarly, 
at 13 weeks, roughly equal proportions (9% and 53%) of 
patients in both groups had PTH levels <150 pg/mL and 
>300 pg/mL, respectively. However, higher proportion 
of patients in the pulse group (39.2%) had 30% or more 
reduction in PTH during the study than the daily group 
(26.4%), which is close to being statistically significant 
(χ2(1) =3.7, P=0.054).
Effects on metabolism of calcium and 
phosphate
At 13 weeks, there were no statistically significant differences 
in mean corrected serum calcium levels between treatment 
groups, and their mean values remained within the normal 
Table 1 Baseline demographic and biomedical characteristics of 
hemodialysis patients by treatment group
Variable Daily group 
(n=88)
Pulse group 
(n=79)
P-value
Age (years) 58.26 (12.7) 56.84 (14.3) 0.498
Gender, n (%) 0.645
Female 41 (46.6) 34 (43.0)
Male 47 (53.4) 45 (57.0)
Diabetes status, n (%) 0.524
Diabetic 50 (56.8) 41 (51.9)
Nondiabetic 38 (43.2) 38 (48.1)
Duration on dialysis (years) 3.7 (3.2) 3.7 (3.5) 0.976
Serum PTH pg/mL 528.4 (550.8) 552.4 (467.5) 0.762
Serum corrected calcium mg/dL 8.9 (0.9) 8.9 (0.9) 0.831
Serum phosphate mg/dL 5.2 (1.5) 5.3 (1.56) 0.665
Alfacalcidol tablets (mcg) 0.7 (0.5) 0.8 (0.6) 0.440
Calcium tablets (mg) 2.6 (2.3) 2.2 (2.1) 0.212
Calcium acetate tablets (mg) 0.7 (1.6) 1.0 (1.9) 0.337
Sevelamer tablets (mg) 0.78 (1.4) 1.2 (2.1) 0.151
Notes: Data are mean (SD), unless otherwise stated.
Abbreviations: PTH, parathyroid hormone; SD, standard deviation.
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range (Table 2). However, mean corrected serum calcium 
increased slightly in the pulse group and dropped slightly in 
the daily group (Table 2; Figure 2). Similarly, we found no 
statistically significant differences in mean serum phosphate 
levels between treatment groups (Table 2). The mean serum 
phosphate levels dropped slightly in a roughly identical way 
in both groups at 13 weeks and their mean values remained 
within the normal range (Table 2; Figure 3).
Factors associated with changes in PTH 
levels at 13 weeks
After controlling for demographic and biomedical character-
istics of patients, the results of repeated measures analysis 
using linear mixed models for PTH levels showed that the 
mean reduction in serum PTH levels at 13 weeks was lower 
in the pulse group than the daily group by 44 pg/mL, but 
this difference was not statistically significant (Table 3). As 
shown in Table 3, age and diabetic status were independently 
associated with changes in serum PTH levels at 13 weeks 
with the respective baseline levels. Increase in age by 1 year 
was associated with decrease in mean serum PTH by 6.7 pg/
dL with the respective baseline levels (P=0.022). At the end 
of the study, diabetic patients had significant reduction in 
mean serum PTH levels by 166 pg/dL (P.037).
Occurrence of side effects
Only two patients in the pulse group reported gastrointestinal 
disturbances. No side effects were reported in the daily group.
Three patients (3.8%) in the pulse group and 5 patients 
(5.7%) in the daily group developed hypercalcemia (cor-
rected serum calcium >10.5 mg/dL) by the end of the study, 
but this was not statistically significant. Similarly, there was 
no statistically significant difference between the two treat-
ment groups in occurrence of hyperphosphatemia (serum 
phosphate >4.5 mg/dL); but hyperphosphatemia occurred 
in 49 patients (62.0%) in the pulse group and in 53 patients 
(60.2%) in the daily group during the study.
Evaluation of compliance
All patients in the pulse group received their individual-
ized alfacalcidol doses by nursing staff at the end of their 
hemodialysis sessions during the study period. Patients in 
the daily group were instructed to intake their alfacalcidol 
doses 7 days a week as usual, but we have no information 
about compliance with alfacalcidol therapy in this group. 
The staff did regular frequent follow-ups to ensure patients 
compliance to their doses as much as possible during the 
period of the study. T
ab
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Figure 1 Mean PTH levels at baseline and at 13 weeks.
Abbreviation: PTH, parathyroid hormone.
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Figure 2 Mean corrected serum calcium levels at baseline and at 13 weeks.
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Discussion
The aim of this randomized controlled trial was to compare 
effectiveness of pulse oral alfacalcidol therapy versus daily 
oral alfacalcidol therapy in suppressing PTH and identify 
demographic and biomedical patients’ characteristics inde-
pendently associated with PTH levels. There were no statisti-
cally significant differences between the two treatment groups 
in baseline demographic and biomedical characteristics. 
Both groups had decreased mean PTH levels at the end of 
the study. The pulse group had more clinically significant 
reduction in mean PTH level at 13 weeks than the daily group, 
but this reduction was not statistically significant. The effect 
of alfacalcidol therapy on metabolism of phosphate at the 
end of the study, characterized by slight reduction in mean 
phosphate levels, was similar in both groups. The mean cor-
rected serum calcium increased slightly in the pulse group 
and dropped slightly in the oral group at the end of the study, 
but remained within normal range in both groups. These 
findings are consistent with prior studies and provide further 
support that pulse oral alfacalcidol therapy is as effective in 
suppressing PTH levels as daily oral alfacalcidol therapy 
without significant increase in the risk of hypercalcemia or 
hyperphosphatemia, with the additive advantage of ensuring 
complete compliance with therapy.12,13
This study showed that mean PTH levels were inversely 
associated with older age and being diabetic. This finding is 
also consisted with previous studies that observed lower PTH 
levels among diabetics16–18 and older hemodialysis patients.16 
The exact mechanism underlying this is not well understood, 
but it was hypothesized to be explained by different factors, 
including malnutrition, inflammation,16,19 and poor glycemic 
control in diabetic patients.16 Lower serum PTH levels among 
diabetic patients may suggest that diabetic patients on hemo-
dialysis might be at greater risk of cardiovascular mortality 
and morbidity than nondiabetic patients. Low serum PTH 
in hemodialysis patients has been linked to increase risk of 
cardiovascular mortality.16,20,21
Figure 3 Mean phosphate levels at baseline and at 13 weeks.
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Table 3 Factors associated with changes in mean PTH levels at 
13 weeks
Variable Effect estimate SE P-value
Treatment group 0.539
Daily Reference category 71.3
Pulse –44.0
Age –6.7 2.9 0.022
Gender 0.995
Female Reference category
Male 0.5 72.3
Diabetic status 0.037
Nondiabetic Reference category
Diabetic –166.4 79.0
Duration on dialysis 
(years)
22.4 11.4 0.051
Abbreviations: PTH, parathyroid hormone; SE, standard error.
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Strengths and limitations
This study included relatively a large number of patients under-
taking hemodialysis in An-Najah National University Hospital. 
The number of hemodialysis patients in this unit represents 
about 20% of all hemodialysis patients’ population in West 
Bank, Palestine.22 So, the sociodemographic and biomedical 
characteristics of enrolled patients are highly likely representa-
tive of the hemodialysis population in West Bank, Palestine. 
Additionally, compliance with alfacalcidol therapy in the pulse 
group was complete during the study as patients received their 
pulse dose of alfacalcidol at the end of each dialysis session 
and this was given by nursing staff in the hemodialysis unit.
One of the limitations of this study is that we were unable 
to use a precise measurement for compliance with alfacal-
cidol therapy in the daily group. However, all patients in the 
daily group were instructed to intake their medications as 
usual 7 days a week. So, it is unlikely that noncompliance 
with medications in the daily group has affected the mag-
nitude and direction of alfacalcidol effects on mean PTH 
levels significantly as our findings are very consistent with 
the findings of prior studies.
Conclusion
This study adds further evidence that pulse oral alfacalcidol 
therapy is as effective in suppressing PTH levels as daily oral 
alfacalcidol therapy, without the significant increase in the 
risk of hypercalcemia or hyperphosphatemia. For clinicians 
treating hemodialysis patients with alfacalcidol, switching 
daily alfacalcidol therapy to thrice-weekly alfacalcidol pulse 
therapy seems safe and convenient, especially for hemodialy-
sis patients with poor compliance with treatment. This study 
also suggests that monitoring and prevention of malnutrition 
with optimal glycemic control in diabetic patients may help in 
minimizing the risk of mortality from cardiovascular disease 
in patients with lower levels of serum PTH.
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